Louisiana State Employees Retirement System Purchases Shares of 11,200 Elevance Health, Inc. $ELV

Louisiana State Employees Retirement System bought a new stake in shares of Elevance Health, Inc. (NYSE:ELV) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,200 shares of the company’s stock, valued at approximately $3,279,000.

Other large investors also recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new position in shares of Elevance Health during the 4th quarter valued at approximately $31,000. J.Safra Asset Management Corp bought a new position in Elevance Health in the 4th quarter worth about $32,000. ORG Partners LLC increased its holdings in Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the period. Dorato Capital Management purchased a new position in shares of Elevance Health during the fourth quarter valued at $41,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Elevance Health in the 4th quarter valued at about $38,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Stock Performance

NYSE:ELV opened at $394.86 on Friday. The company has a fifty day simple moving average of $383.03 and a two-hundred day simple moving average of $349.01. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $426.98. The company has a market cap of $85.75 billion, a price-to-earnings ratio of 16.80, a price-to-earnings-growth ratio of 2.24 and a beta of 0.67.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter last year, the business posted $11.97 EPS. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s dividend payout ratio is currently 29.26%.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by company insiders.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Nephron Research issued forecasts implying continued earnings growth for Elevance Health, including FY2027 EPS of $28.95, which may reinforce confidence in the company’s long-term profitability. Elevance Health stock and earnings report
• Positive Sentiment: Analyst commentary highlighted Carelon as a potential growth engine for ELV, with the unit expected to support revenues, care efficiency, and future earnings growth. Carelon growth article
• Neutral Sentiment: Elevance Health’s FY2026 EPS estimate from Nephron Research came in at $25.73, a bit below the current consensus of $26.92, which is not a major negative but may temper some near-term enthusiasm.
• Neutral Sentiment: Additional articles focused on what to expect from Q2 2026 earnings and investor reaction to a platform deal, but they did not provide a clear new fundamental surprise for the stock. Q2 2026 earnings expectations Investor reaction article

Analyst Ratings Changes

A number of brokerages have recently issued reports on ELV. Robert W. Baird lifted their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Bank of America raised their target price on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a report on Thursday, June 4th. Morgan Stanley increased their price target on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 4th. Sanford C. Bernstein boosted their target price on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Finally, Guggenheim increased their price target on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a report on Friday, April 24th. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $416.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.